At Orchard, we’re committed to working closely with physicians and others in the healthcare community to advance research into ex vivo autologous gene therapy and improve outcomes for people affected by rare inherited diseases. This page is our portal for Healthcare Professionals where you can access the latest information about our products and events, training modules as well as support materials for you and your patients.
Representative request
Orchard will contact you shortly to setup a time for a visit. We look forward to helping you find the right information on gene therapy and our products. For more information and to apply, please contact info@orchard-tx.com
Independent Medical Education
Orchard supports independent medical education on our therapeutic areas of interest and on emerging developments in gene therapy. For more information and to apply, please contact medinfo@orchard-tx.com.
Investigator-initiated Research
Orchard supports investigator-initiated research on the diagnosis, natural history and other topics relevant to our indications. For more information and to apply, please contact medinfo@orchard-tx.com.
Clinical trials
Orchard and our research partners are conducting clinical trials of investigational gene therapies for a number of rare, inherited diseases, including primary immune deficiencies, diseases of the brain and blood disorders. For more information about these trials, explore our pipeline page or contact a member of Orchard medical information at medinfo@orchard-tx.com.
Adverse Events
Adverse events should be reported. You can report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ (for the UK) or by downloading a copy of the adverse reaction report form and email it to medsafety@hpra.ie (for Ireland, see more info on https://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects or call (01) 676 4971). By reporting side effects, you can help provide more information on the safety of this medicine.
Adverse events should also be reported to drugsafety@orchard-tx.com.
UK-NoP-2400003, February 2024
